Clinical trials: Rabies Virus Infection
Treatment of Rabies
Rabies Treatment by Exposure of Patient to X-Ray
x-ray has been proven to kill Rabies virus in vitro, so the investigators can use it in treatment of rabies infected patients.
- Trial name
- NCT04261322
- Testing
- x ray exposure
- Volunteers
- 4 people
- Sponsor
- National Institute For Research On Endemic Diseases And Liver, Egypt
Rabies
Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vaccination in Obese Patients
A single center, prospective cohort, open-label study of rabies post exposure program with equine rabies immunoglobulin (ERIG) and purified chick-embryo cell (PCEC) rabies vaccine in WHO category III exposed patients at Siriraj…
- Trial name
- NCT03093545
- Testing
- Equine Rabies Immunoglobulin, Purified chick-embryo cell rabies vaccine
- Where
- Thailand
- Volunteers
- 60 people
- Sponsor
- Mahidol University
Rabies
Safety and Immunogenicity of the Inactivated Rabies Vaccine RABIVAX-S Administered Intramuscularly and Intradermally
Randomized, open-label, prospective, before-and-after comparison study in the same group. Subjects suitable for the study will be randomly assigned at a ratio of 1:1 (block 4) to use the study vaccine by one of two routes of…
- Trial name
- NCT05937113
- Testing
- RABIVAX-S
- Where
- Vietnam
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Vietnam Military Medical University
Rabies
Immunity Persistence After Abridged Intradermal Rabies PEP
After exposure, rabies can be prevented in almost 100% of cases by the administration of sufficient and timely post-exposure prophylaxis (PEP).
- Trial name
- RESIST-3 (NCT04829630)
- Testing
- rabies vaccine
- Where
- 2 sites in Cambodia, Madagascar
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
HIV Infections
A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers
To compare the safety of ALVAC-HIV vCP205 to that of ALVAC-RG vCP65 rabies glycoprotein, delivered by a variety of mucosal routes. To evaluate the antibody, humoral, and cellular immune responses resulting from ALVAC-HIV vCP205.
- Trial name
- NCT00000884
- Testing
- MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65)
- Where
- 6 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Communicable Disease Transmission, Zoonotic Disease
A Bridging Study of the SYN023 on Healthy Adult Subjects
The Phase I bridging clinical trial is to evaluate on the safety, pharmacokinetics (PK), pharmacodynamics (PD) and ADA of a single intramuscular injection of recombinant anti-rabies human monoclonal antibody injection (SYN023)…
- Conditions
- Communicable Disease Transmission, Zoonotic Disease, Rabies Human, Vaccine Reaction
- Trial name
- NCT04495569
- Testing
- recombinant anti-rabies human monoclonal antibody injection (SYN023), Rabies Vaccine
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Rabies
Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG
This is a first-in-human, open-label, dose escalation, phase I clinical trial to assess the safety and immunogenicity of the candidate ChAdOx2 RabG vaccine in healthy UK volunteers aged 18-65.
- Trial name
- NCT04162600
- Testing
- ChAdOx2 RabG, Inactivated Rabies Vaccine
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Vaccine Reaction
A Comparison of Safety and Immunogenicity of Rabies Pre Exposure Prophylaxis Regimen Between Gvt of India Approved and WHO Approved.
The goal of this clinical trial is to compare WHO recommended PrEP Vaccination Schedule, 2 doses 0.2ml 2 sites (0.1ml each site) on day 0 and day 7 and Government of India currently recommended PrEP Schedule, 0.1ml 3 doses on day…
- Trial name
- NCT06066294
- Testing
- Regimen 1, Regimen 2
- Where
- India
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Kempegowda Institute of Medical Sciences, Bangalore
Rabies Prevention, Rabies Exposure
Study of Intradermal Administration of PCEC Rabies Vaccine
The purpose of this study is to determine immunogenicity and safety of intradermal administration of the PCEC rabies vaccine in adults.
- Trial name
- Rabies-ID (NCT01044199)
- Testing
- PCEC rabies vaccine given intradermally, PCEC rabies vaccine administered intramuscularly
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Rabies
Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)
To describe the immunogenicity and safety of two dosages of Sinovac rabies vaccine, as well as compared the differences with the marked WHO PQ rabies vaccine Verorab® in a post-exposure prophylaxis (PEP) schedule.
- Trial name
- NCT07055880
- Testing
- Rabies Vaccine (Serum-free Vero Cell), Freeze-dried, Verorab®
- Where
- Pakistan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Rabies Human, Antibody
Prevention of Rabies With Four Doses of Rabies Vaccine
To evaluate the non inferiority of the immunogenicity of the test vaccine inoculated according to the four dose immunization program over the five dose immunization program and the batches consistency of immunogenicity according…
- Trial name
- NCT05545371
- Testing
- immunization procedures
- Where
- China
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Changchun Zhuoyi Biological Co., Ltd
Rabies Post-exposure Prophylaxis
SYN023 With Rabies Vaccine in Healthy Pediatric Subjects
This study is a randomized, double-blind, active-controlled design. The goal is to evaluate the safety, pharmacokinetics and pharmacodynamic of SYN023 in combination with rabies vaccine in healthy participants under 18 years of…
- Trial name
- NCT07342257
- Testing
- SYN023, Rabies Vaccine, HRIG
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Rabies
Safety Study of Rabies Vaccine INDIRAB® Five Doses (0.5ml) Post Exposure Administered Intramuscularly
An open label, non-comparative bridging study to evaluate the safety of Rabies vaccine INDIRAB® in Healthy Vietnamese volunteer aged from 5 years old.
- Trial name
- NCT02729168
- Testing
- Human rabies vaccine
- Where
- Vietnam
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products
Rabies
Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects
The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in comparison with Human rabies immune globulin (HRIG) comparator product. 2.
- Trial name
- KAMRAB-003 (NCT02040090)
- Testing
- Active rabies vaccine (US-FDA approved)
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Kamada, Ltd.
Plasmodium Falciparum Malaria
Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali
Malaria is a disease that affects many people in Africa. Malaria is caused by germs spread by mosquito bites. The purpose of this study is to compare the number of children who get malaria after receiving an experimental malaria…
- Trial name
- NCT00460525
- Testing
- FMP2.1/AS02A, Rabies Vaccine
- Where
- Mali
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Rabies
Clinical Trial of Freeze-dried Human Rabies Vaccine (Human Diploid Cells)
The Phase 3 clinical trial of freeze-dried human rabies vaccine (human diploid cells) adopted a randomized, blinded, parallel control,non-inferiority design,and administered vaccines to participants aged 10 to 60 years with…
- Trial name
- NCT07028801
- Testing
- Freeze-dried human rabies vaccine (human diploid cells)
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Ningbo Rongan Biological Pharmaceutical Co., Ltd.
Rabies
Safety and Immunogenicity of Purified Verocell Rabies Vaccine PVRV Administered Intramuscularly and Intradermally
Rabies is fatal disease but preventable with rabies vaccines and immunoglobulins, conventionally involves intramuscular (IM) administration of the vaccine.
- Trial name
- NCT06433440
- Testing
- PVRV
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- University of Peshawar
Safety, Immunogenicity
Safety and Immunogenicity of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans
The purpose of this study is to evaluate the safety and immunogenicity of freeze-dried rabies vaccine (MRC-5 cells)in different age health human populations, according to the traditional Essen methods (1-1-1-1-1) vaccination.
- Trial name
- NCT02288286
- Testing
- 2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 10-20 years old, 2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 21-50 years old, 2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 51-60 years old
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Beijing Center for Disease Control and Prevention
Rabies
Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults
The purpose of this study is to generate data in human on immunogenicity and safety of Purified Vero Rabies Vaccine (VRVg) in support of the vaccine registration.
- Trial name
- NCT00948272
- Testing
- Purified Vero Rabies Vaccine - Serum Free, Purified inactivated rabies vaccine
- Where
- 6 sites in France
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules
This study was planned to establish the non-inferiority of Rabipur administered as simulated post exposure Zagreb schedule as compared to Essen schedule, in healthy Indian adult subjects.
- Trial name
- NCT01365494
- Testing
- Purified Chick Embryo Cell Inactivated Rabies Vaccine
- Where
- 3 sites in India
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines